ProtoKinetix, Incorporated (PKTX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Marietta, OH, United States. The current CEO is Michael Richard Guzzetta.
PKTX has IPO date of 2002-04-22, listed on the Other OTC, a market capitalization of $2.72M.
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.
